Monthly Archives: novembre 2018

//novembre

Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T15:33:42+02:00novembre 30th, 2018|Publication, TG1050|Commentaires fermés sur Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study

Claire Fournier, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T14:15:26+02:00novembre 7th, 2018|Publication, TG1050|Commentaires fermés sur Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study

Transgene et BioInvent présentent des données positives soutenant le co-développement d’un virus oncolytique de nouvelle génération exprimant un anticorps anti-CTLA-4

20181107 SITC Joint BioInvent Transgene FR

By |2019-06-03T18:46:18+02:00novembre 7th, 2018|Communiqué de presse, Invir.IO|Commentaires fermés sur Transgene et BioInvent présentent des données positives soutenant le co-développement d’un virus oncolytique de nouvelle génération exprimant un anticorps anti-CTLA-4